

ASX Release

SUDA Share Placement to Raise \$2.76m

- SUDA to raise \$2.76 million in an oversubscribed placement
- SUDA cash balance strong enough to carry the company's development program for 12 months
- Suda's cash balance will enable the company to remained focused on current products and to evaluate new assets for a potential acquisition

PERTH, AUSTRALIA – 16 Dec 2020: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, is pleased to announce that they have received firm commitments for a capital raising by way of a placement of up to 76,708,975 ordinary shares to existing and new professional and sophisticated investors to raise \$2,761,523 before costs. New shares issued under the Placement will rank equally with existing SUDA shares.

The placement to strong supporters of the company will provide SUDA with funding to maintain its current developments for twelve months. The additional funding will assist management to continue evaluating new assets that have been identified and are being considered for acquisition. As outlined in the AGM, the Company's areas of focus are oncology and the central nervous system and the Company is looking to secure technologies in the pre-clinical or clinical stages of drug development.

SUDA's CEO and MD, Dr Michael Baker, said "we are pleased with the demand for investment in SUDA from sophisticated and professional investors. We have a portfolio of products under development, and we are evaluating technologies for a potential acquisition to expand our pipeline in the value-adding stages of drug development. This capital raising strengthens our financial position giving us 12 months before the company will need additional capital."

Baker Young Limited acted as Lead Manager for the Offer, which was priced at \$0.036 per share representing an 8% discount to the weighted average closing price of Shares over the past 10 days to 11 December 2020 (being the last trading day before announcement of the Offer). The Placement Shares will be issued under the Company's existing capacity under ASX Listing Rule 7.1 and 7.1A. This equates to 46,025,385 under Listing Rule 7.1 and 30,683,590 under ASX Listing Rule 7.1A.

The SUDA Directors and Management will contribute up to \$50,000 as part of the Placement, subject to the approval of shareholders in respect of the Directors' participation.

For and on behalf of the Board and for further information please contact:

Dr Michael Baker

Chief Executive Officer & Managing Director

SUDA Pharmaceuticals Ltd

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem tartrate for the treatment of short-term insomnia. ZolpiMist is approved by the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of migraine headache, motion sickness, drug resistant epilepsy and certain cancers.

For more information, visit www.sudapharma.com